📰 Acousia News
Acousia News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Acousia. Real-time updates on events, politics, business and more.
February 15, 2024
Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose cisplatin-based chemotherapy regimens (cis-Pt ≥300 mg/m2).
November 24, 2022
TÜBINGEN, Germany, Nov. 24, 2022 /PRNewswire/ -- Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department
May 11, 2022
TÜBINGEN, Germany, May 11, 2022 /PRNewswire/ -- Acousia Therapeutics GmbH will be presenting data on the company's clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd
May 5, 2022
TÜBINGEN, Germany, May 5, 2022 /PRNewswire/ -- ACOU085, the lead candidate from Acousia Therapeutics, has been administered to the first patient with age-related hearing loss (presbycusis) in
February 4, 2022
TÜBINGEN, Germany, Feb. 4, 2022 /PRNewswire/ -- Acousia Therapeutics GmbH - along with its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department